Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma.
about
Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switchEntirely Carbohydrate-Based Vaccines: An Emerging Field for Specific and Selective Immune ResponsesMelanoma Peptide Vaccines.Human IgM antibody therapy for HIV-1 infection.Effective, nonsensitizing vaccination with culture filtrate proteins against virulent Mycobacterium bovis infections in mice.Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes.Preclinical evaluation of the synthetic adjuvant SQS-21 and its constituent isomeric saponins.Ganglioside GD3 promotes cell growth and invasion through p130Cas and paxillin in malignant melanoma cells.An overview of cancer immunotherapy.Novel strategies and therapeutics for the treatment of prostate carcinoma.Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine.Carbohydrate-based vaccines with a glycolipid adjuvant for breast cancerImmunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trialChitosan nanoparticles act as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in miceThe case for polyvalent cancer vaccines that induce antibodies.Application of Quillaja saponaria extracts as oral adjuvants for plant-made vaccines.Immunological adjuvant effect of the peptide fraction from the larvae of Musca domestica.Evaluation of Selected Immunomodulatory Glycoproteins as an Adjunct to Cancer Immunotherapy.Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challengesMeta-Analysis on Randomized Controlled Trials of Vaccines with QS-21 or ISCOMATRIX Adjuvant: Safety and Tolerability.Carbohydrate vaccines as immunotherapy for cancer.A Fully Synthetic Self-Adjuvanting Globo H-Based Vaccine Elicited Strong T Cell-Mediated Antitumor Immunity.Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer.Evaluation of widely consumed botanicals as immunological adjuvantsThe safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteersThe known immunologically active components of Astragalus account for only a small proportion of the immunological adjuvant activity when combined with conjugate vaccines.Immunization with N-propionyl polysialic acid-KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci.In planta production of plant-derived and non-plant-derived adjuvants.Carbohydrate-based vaccines: challenges and opportunities.Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems.Recent advances in developing synthetic carbohydrate-based vaccines for cancer immunotherapies.The sweet side of tumor immunotherapy.Recent advances in vaccine adjuvants for systemic and mucosal administration.Carbohydrate-based vaccine adjuvants - discovery and development.Chronic Myeloid Leukemia: Immunobiology and Novel Immunotherapeutic Approaches.Quillaja Saponin Variants with Central Glycosidic Linkage Modifications Exhibit Distinct Conformations and Adjuvant ActivitiesImmunological evaluation of the entirely carbohydrate-based Thomsen-Friedenreich - PS B conjugate.QS-21 enhances the early antibody response to oil adjuvant foot-and-mouth disease vaccine in cattle.Carbohydrate vaccines that induce antibodies against cancer. 2. Previous experience and future plans.Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21.
P2860
Q24676179-28FF1CF7-0898-41F9-8EBF-D906D13D2FE9Q26746887-20FD49BC-9621-4757-ADB0-85EDE8898E3DQ30305778-C8D64D4D-7EB6-4808-828B-238A39F908A0Q33753260-CE8CD7DB-5DF8-41DC-B635-13999A6EF499Q33767136-C16B00B8-6AC2-4E8C-B67A-E73ABF421DD7Q33784161-CCBC6EE0-D125-4330-A071-6BD268F64BF9Q33899683-84426A65-B5F1-45C3-BBF0-B222938F4518Q33904439-32EB0EE3-378B-4DDC-BD17-1FDC812E709CQ33940388-742D6276-5C2A-44C4-88F6-3A9B4E06D572Q34043331-9101B40F-D349-4BF5-B8BD-DD8F8AD636B2Q34504625-CF22DA09-65E2-4613-BCB6-0C0886248888Q34565029-54203FB0-E29A-4776-885B-D05C72B67341Q34720308-2696CEC2-655E-4DF4-8982-C5FEA0E6B301Q35091726-BE43A181-C9D7-47E8-9F7C-08F860CA2E4AQ35193433-DDA57C24-D8A3-44E9-919B-50BC2E9A7E2AQ35790886-2C0891B1-3E59-47A6-9D7D-BF6D03452D4BQ35859313-88FE6CDC-495D-4306-992B-05DE6975733BQ35901088-0012CEF8-EDB9-4A04-8A5F-A84741A53F50Q35951545-117CED63-6926-4737-B6AD-7FB4AFDDA03EQ36009558-4562F9DE-A22B-4240-9D83-7A152F038DD8Q36201691-2F4563B6-0565-4BE7-8183-63241279C756Q36604334-8AACBC7D-EBE6-4781-821A-BC196B3C204AQ36856279-02AAFD8F-AC13-405C-B1A1-DA0D0CF9FCA9Q36932370-B11DD1A0-6307-441E-B109-30882880709BQ36945335-95554DDA-7F33-4F56-B92D-7A7432AB80AEQ37011520-21030FE0-F9BF-4099-86CC-8BDB4D679D59Q37066964-93C25C5D-BDD0-4A9A-83F3-3EE70409053FQ37776716-A1FE3D5F-EA73-4DCD-958D-1CBD49D586CDQ37810597-C9C560A4-F406-4DA0-911E-7A82CFFFDD59Q37867102-483C9E48-3229-42EA-ADA8-5C626A936A5EQ37993590-58145DBC-95A3-4D8F-A739-5873017040DEQ38031282-914EDC5C-C7C7-41D8-9DA6-6A4B89730959Q38553059-4CAF2614-DA31-4A13-97DE-D5B766A02B93Q38587300-8716D1C8-1AF1-4020-93F4-5E9887180836Q38684223-918F2924-13A7-47B2-BFDC-0FC0025B635EQ39236688-5B94901A-A497-497C-9C3D-B92CD4CAE6BFQ39935587-2F38E669-199C-491E-BC97-029E19A5D36AQ40636746-60D227F5-D9D8-4BC0-BCCD-9BFA953D9E77Q40879087-49756903-F035-4399-9F0A-A8A00B24473EQ40896263-09664EA2-89C7-4E6F-BD7A-11AF2E1CCBB5
P2860
Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Phase 1 trial of immunological ...... ients with malignant melanoma.
@en
type
label
Phase 1 trial of immunological ...... ients with malignant melanoma.
@en
prefLabel
Phase 1 trial of immunological ...... ients with malignant melanoma.
@en
P2093
P1433
P1476
Phase 1 trial of immunological ...... ients with malignant melanoma.
@en
P2093
C R Kensil
D Marciani
M J Newman
P O Livingston
P304
P356
10.1016/S0264-410X(94)80052-2
P407
P577
1994-11-01T00:00:00Z